Adjuvant Docetaxel–Cyclophosphamide Versus Anthracycline–Taxane Chemotherapy in Stage I–III HR-Positive/HER2-Negative Breast Cancer: A Real-World Propensity Score Overlap-Weighted Cohort Study
Adjuvantes Docetaxel–Cyclophosphamid versus Anthrazyklin–Taxan-Chemotherapie bei Brustkrebs Stadium I–III, HR-positiv/HER2-negativ: Real-World-Kohortenstudie mit Propensity-Score-Overlap-Weighting
Journal of Clinical Medicine · 03.11.2026 · 15 (21) · 8568
DOI: 10.3390/jcm15218568 ↗Auf einen Blick
In 361 Patient:innen mit frühem HR-positivem/HER2-negativem Brustkrebs zeigte sich nach Adjuvanz mit TC vs. Anthrazyklin–Taxan kein statistisch signifikanter Unterschied im 3-Jahres-DFS. Die Ereigniszahl war gering.
Fragestellung
Vergleicht sich das krankheitsfreie Überleben unter adjuvantem Docetaxel–Cyclophosphamid (TC) und Anthrazyklin–Taxan-Chemotherapie bei Stadium I–III HR-positivem/HER2-negativem Brustkrebs?
Methode
Retrospektive Single-Center-Kohortenstudie mit Propensity-Score-Overlap-Weighting; Patient:innen nach Operation und adjuvanter TC- oder Anthrazyklin–Taxan-Chemotherapie zwischen 2019 und 2025.
Ergebnisse
361 Patient:innen; 201 mit TC, 160 mit Anthrazyklin–Taxan. 12 DFS-Ereignisse. Gewichtetes 3-Jahres-DFS: 99,2 % vs. 96,5 %; absolute Differenz 2,68 Prozentpunkte (95 %-KI −1,81 bis 10,03).
Einschränkungen
Wenige Ereignisse und relativ kurze Nachbeobachtung; daraus keine Schlussfolgerung zu Äquivalenz oder Nichtunterlegenheit.
Schlussfolgerung der Autor:innen
Nach Adjustierung zeigte sich kein statistisch signifikanter Unterschied im 3-Jahres-DFS. Die Autor:innen empfehlen eine individualisierte Wahl der adjuvanten Chemotherapie und weitere Bestätigung in größeren Kollektiven.
Kernaussagen
- Kein signifikanter Unterschied im 3-Jahres-DFS nach Adjustierung
- Gewichtete Differenz 2,68 Prozentpunkte (95 %-KI −1,81 bis 10,03)
- Wenige Ereignisse und kurze Nachbeobachtung begrenzen die Aussagekraft
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 03.11.2026. Verfasst von Perihan Perkin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ankara Bilkent City Hospital, 06800 Ankara, Türkiye. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: The optimal adjuvant chemotherapy regimen remains uncertain for some patients with hormone receptor (HR)-positive/HER2-negative early breast cancer, particularly regarding the incremental benefit of anthracyclines. We compared real-world outcomes with docetaxel-plus-cyclophosphamide (TC) and anthracycline–taxane chemotherapy.
Methods
This retrospective single-center cohort included patients with stage I–III HR-positive/HER2-negative breast cancer who underwent surgery and received adjuvant TC or anthracycline–taxane chemotherapy between 2019 and 2025. Patients receiving neoadjuvant systemic therapy were excluded. Disease-free survival (DFS) was the primary outcome and overall survival (OS) the secondary outcome. Propensity score overlap weighting adjusted for measured baseline differences was used; the absolute difference in weighted 3-year DFS was the primary adjusted measure.
Results
Among 361 patients, 201 received TC and 160 anthracycline–taxane chemotherapy. The anthracycline–taxane group had higher baseline clinicopathologic risk. Median follow-up was 39.0 months. Twelve DFS events occurred (TC, n = 3; anthracycline–taxane, n = 9). Unadjusted 3-year DFS was 99.0% versus 96.6% (p = 0.096), and 3-year OS was 99.4% versus 99.1% (p = 0.725). The overlap-weighted analysis included 346 patients and achieved adequate covariate balance. Weighted 3-year DFS was 99.2% with TC and 96.5% with anthracycline–taxane chemotherapy, an absolute difference of 2.68 percentage points (95% CI, −1.81 to 10.03). Sensitivity analysis yielded similar results (2.70 percentage points; 95% CI, −1.76 to 9.87).
Conclusions
No statistically significant difference in 3-year DFS was demonstrated after adjustment. Limited events and relatively short follow-up preclude conclusions regarding equivalence or noninferiority. These findings support individualized adjuvant chemotherapy selection and warrant confirmation in larger cohorts with longer follow-up.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Ankara Bilkent City Hospital, 06800 Ankara, Türkiye.
ORCID-Profile: Perihan Perkin, Derya Sarikaya, Ugur Ozberk, Efnan Algin, Oznur Bal, Gokhan Ucar
Zitieren
APA
Perkin, P., Sarikaya, D., Karakas, H., Ozberk, U., Bilgin, B., Algin, E., Bal, O., Dede, D. S., & Ucar, G. (2026). Adjuvant Docetaxel–Cyclophosphamide Versus Anthracycline–Taxane Chemotherapy in Stage I–III HR-Positive/HER2-Negative Breast Cancer: A Real-World Propensity Score Overlap-Weighted Cohort Study. Journal of Clinical Medicine, 15(21), 8568. https://doi.org/10.3390/jcm15218568
Vancouver
Perkin P, Sarikaya D, Karakas H, Ozberk U, Bilgin B, Algin E, et al. Adjuvant Docetaxel–Cyclophosphamide Versus Anthracycline–Taxane Chemotherapy in Stage I–III HR-Positive/HER2-Negative Breast Cancer: A Real-World Propensity Score Overlap-Weighted Cohort Study. Journal of Clinical Medicine. 2026;15(21):8568. doi:10.3390/jcm15218568
BibTeX
@article{Perkin2026,
author = {Perkin, Perihan and Sarikaya, Derya and Karakas, Hilal and Ozberk, Ugur and Bilgin, Burak and Algin, Efnan and Bal, Oznur and Dede, Didem Sener and Ucar, Gokhan},
title = {Adjuvant Docetaxel–Cyclophosphamide Versus Anthracycline–Taxane Chemotherapy in Stage I–III HR-Positive/HER2-Negative Breast Cancer: A Real-World Propensity Score Overlap-Weighted Cohort Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8568},
doi = {10.3390/jcm15218568}
}
EUVIMED